Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2015

Open Access 01-12-2015 | Research

MicroRNA-184 inhibits cell proliferation and invasion, and specifically targets TNFAIP2 in Glioma

Authors: Zhe Cheng, Hang Zhou Wang, Xuetao Li, Zhiwu Wu, Yong Han, Yanyan Li, Guilin Chen, Xueshun Xie, Yulun Huang, Ziwei Du, Youxin Zhou

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2015

Login to get access

Abstract

Background

miRNA-184 is an oncogene in human hepatocellular carcinoma but acts as a tumor suppressor in tongue squamous cell carcinoma. Studies have shown that miR-184 was down-regulated in glioma and TNFα-induced protein 2 (TNFAIP2) was closely related to tumorigenesis. This study aimed to determine the functions of miR-184 in glioma and the mechanisms of miRNA-184-TNFAIP2 mediated glioma progression.

Methods

Real-time reverse-transcription PCR detected expression of miR-184 and TNFAIP2. U87 and U251 cells were transfected with miR-184 mimic, inhibitor, or negative control miRNA, and their invasion abilities were assayed. Cellular proliferation was measured by the cell counting kit-8 assay. miR-184 effects on glioma cell apoptosis and cell cycle were assessed by flow cytometer. Biological information software have predicted that miR-184 could target TNFα-induced protein 2 (TNFAIP2), Which was further validated by Western blot and qRT-PCR in glioma cells. In vivo, U87 cells transduced with either lentiviral over-expressed miR-184 or control lentivirus were injected into nude mice subcutaneously and intracranial respectively.

Results

Expression of miR-184 was significantly lower in glioma tissues and cell-lines compared to normal brain tissues. Protein and mRNA expression of TNFAIP2 were inversely correlated with miR-184 in glioma. In vitro, proliferation and invasion abilities were also decreased in U87 and U251 cells after transfection with miR-184 mimic. In vivo, the xenografted tumor size in the miR-184 overexpressing group were smaller than the miR-NC group. Concordantly, U87 and U251 cells transfected with miR-184 mimic had a higher apoptosis rate, triggering an accumulation of cells at the G0/G1 phase and decreased cells in S-phase.

Conclusions

miR-184 could regulate TNFAIP2 expression and affected its translation in glioma. miR-184 could also inhibit glioma progression and might serve as a novel therapeutic target in glioma.
Appendix
Available only for authorised users
Literature
1.
Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95(2):190–8. doi:10.3171/jns.2001.95.2.0190.CrossRefPubMed
2.
Wang Q, Li P, Li A, Jiang W, Wang H, Wang J, et al. Plasma specific miRNAs as predictive biomarkers for diagnosis and prognosis of glioma. J Exp Clin Cancer Res. 2012;31:97. doi:10.1186/1756-9966-31-97.CrossRefPubMedCentralPubMed
3.
Zhou Y, Su Z, Huang Y, Sun T, Chen S, Wu T, et al. The Zfx gene is expressed in human gliomas and is important in the proliferation and apoptosis of the human malignant glioma cell line U251. J Exp Clin Cancer Res. 2011;30:114. doi:10.1186/1756-9966-30-114.CrossRefPubMedCentralPubMed
4.
Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359(5):492–507. doi:10.1056/NEJMra0708126.CrossRefPubMed
5.
Li X, Ling N, Bai Y, Dong W, Hui GZ, Liu D, et al. MiR-16-1 plays a role in reducing migration and invasion of glioma cells. Anatomical Record (Hoboken NJ 2007). 2013;296(3):427–32. doi:10.1002/ar.22626.CrossRef
6.
7.
Schickel R, Boyerinas B, Park SM, Peter ME. MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene. 2008;27(45):5959–74. doi:10.1038/onc.2008.274.CrossRefPubMed
8.
Tufekci KU, Meuwissen RL, Genc S. The role of microRNAs in biological processes. Methods in molecular biology (Clifton, NJ). 2014;1107:15–31. doi:10.1007/978-1-62703-748-8_2.CrossRef
9.
Silber J, James CD, Hodgson JG. microRNAs in gliomas: small regulators of a big problem. Neuromolecular Med. 2009;11(3):208–22. doi:10.1007/s12017-009-8087-9.CrossRefPubMed
10.
11.
Nomura T, Kimura M, Horii T, Morita S, Soejima H, Kudo S, et al. MeCP2-dependent repression of an imprinted miR-184 released by depolarization. Hum Mol Genet. 2008;17(8):1192–9. doi:10.1093/hmg/ddn011.CrossRefPubMed
12.
Weitzel RP, Lesniewski ML, Greco NJ, Laughlin MJ. Reduced methyl-CpG protein binding contributing to miR-184 expression in umbilical cord blood CD4+ T-cells. Leukemia. 2011;25(1):169–72. doi:10.1038/leu.2010.227.CrossRefPubMed
13.
Wu GG, Li WH, He WG, Jiang N, Zhang GX, Chen W, et al. Mir-184 post-transcriptionally regulates SOX7 expression and promotes cell proliferation in human hepatocellular carcinoma. PLoS One. 2014;9(2):e88796. doi:10.1371/journal.pone.0088796.CrossRefPubMedCentralPubMed
14.
Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP, Wei WI. Mature miR-184 as Potential Oncogenic microRNA of Squamous Cell Carcinoma of Tongue. Clin Cancer Res off J Am Assoc Cancer Res. 2008;14(9):2588–92. doi:10.1158/1078-0432.ccr-07-0666.CrossRef
15.
Chen Y, Stallings RL. Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res. 2007;67(3):976–83. doi:10.1158/0008-5472.can-06-3667.CrossRefPubMed
16.
Tivnan A, Foley NH, Tracey L, Davidoff AM, Stallings RL. MicroRNA-184-mediated inhibition of tumour growth in an orthotopic murine model of neuroblastoma. Anticancer Res. 2010;30(11):4391–5.PubMed
17.
Malzkorn B, Wolter M, Liesenberg F, Grzendowski M, Stuhler K, Meyer HE, et al. Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. Brain Pathol (Zurich, Switzerland). 2010;20(3):539–50. doi:10.1111/j.1750-3639.2009.00328.x.CrossRef
18.
Emdad L, Janjic A, Alzubi MA, Hu B, Santhekadur PK, Menezes ME, et al. Suppression of miR-184 in malignant gliomas upregulates SND1 and promotes tumor aggressiveness. Neuro-oncology. 2014. doi:10.1093/neuonc/nou220
19.
Sarma V, Wolf FW, Marks RM, Shows TB, Dixit VM. Cloning of a novel tumor necrosis factor-alpha-inducible primary response gene that is differentially expressed in development and capillary tube-like formation in vitro. J Immunol (Baltimore, Md : 1950). 1992;148(10):3302–12.
20.
Rusiniak ME, Yu M, Ross DT, Tolhurst EC, Slack JL. Identification of B94 (TNFAIP2) as a potential retinoic acid target gene in acute promyelocytic leukemia. Cancer Res. 2000;60(7):1824–9.PubMed
21.
Chen LC, Chen CC, Liang Y, Tsang NM, Chang YS, Hsueh C. A novel role for TNFAIP2: its correlation with invasion and metastasis in nasopharyngeal carcinoma. Modern Pathol Off J United States Canadian Acad Pathol Inc. 2011;24(2):175–84. doi:10.1038/modpathol.2010.193.CrossRef
22.
Liu Z, Wei S, Ma H, Zhao M, Myers JN, Weber RS, et al. A functional variant at the miR-184 binding site in TNFAIP2 and risk of squamous cell carcinoma of the head and neck. Carcinogenesis. 2011;32(11):1668–74. doi:10.1093/carcin/bgr209.CrossRefPubMedCentralPubMed
23.
Lee KH, Chen YL, Yeh SD, Hsiao M, Lin JT, Goan YG, et al. MicroRNA-330 acts as tumor suppressor and induces apoptosis of prostate cancer cells through E2F1-mediated suppression of Akt phosphorylation. Oncogene. 2009;28(38):3360–70. doi:10.1038/onc.2009.192.CrossRefPubMed
24.
Yekta S, Shih IH, Bartel DP. MicroRNA-directed cleavage of HOXB8 mRNA. Sci (New York, NY). 2004;304(5670):594–6. doi:10.1126/science.1097434.CrossRef
25.
26.
Zhen Y, Liu Z, Yang H, Yu X, Wu Q, Hua S, et al. Tumor suppressor PDCD4 modulates miR-184-mediated direct suppression of C-MYC and BCL2 blocking cell growth and survival in nasopharyngeal carcinoma. Cell Death Dis. 2013;4:e872. doi:10.1038/cddis.2013.376.CrossRefPubMedCentralPubMed
27.
Peng B, Li D, Qin M, Luo D, Zhang X, Zhao H, et al. MicroRNA218 inhibits glioma migration and invasion via inhibiting glioma-associated oncogene homolog 1 expression at N terminus. Tumour Biol J Int Soc Oncodev Biol Med. 2014;35(4):3831–7. 10.1007/s13277-013-1507-3.CrossRef
28.
Foley NH, Bray IM, Tivnan A, Bryan K, Murphy DM, Buckley PG, et al. MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2. Mol Cancer. 2010;9:83. doi:10.1186/1476-4598-9-83.CrossRefPubMedCentralPubMed
29.
Yuan Q, Gao W, Liu B, Ye W. Upregulation of miR-184 enhances the malignant biological behavior of human glioma cell line A172 by targeting FIH-1. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol. 2014;34(4):1125–36. doi:10.1159/000366326.CrossRef
30.
Xu Y, Ma H, Yu H, Liu Z, Wang LE, Tan D, et al. The miR-184 binding-site rs8126 T > C polymorphism in TNFAIP2 is associated with risk of gastric cancer. PLoS One. 2013;8(5):e64973. doi:10.1371/journal.pone.0064973.CrossRefPubMedCentralPubMed
31.
Chen CC, Liu HP, Chao M, Liang Y, Tsang NM, Huang HY, et al. NF-kappaB-mediated transcriptional upregulation of TNFAIP2 by the Epstein-Barr virus oncoprotein, LMP1, promotes cell motility in nasopharyngeal carcinoma. Oncogene. 2014;33(28):3648–59. doi:10.1038/onc.2013.345.CrossRefPubMed
Metadata
Title
MicroRNA-184 inhibits cell proliferation and invasion, and specifically targets TNFAIP2 in Glioma
Authors
Zhe Cheng
Hang Zhou Wang
Xuetao Li
Zhiwu Wu
Yong Han
Yanyan Li
Guilin Chen
Xueshun Xie
Yulun Huang
Ziwei Du
Youxin Zhou
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2015
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-015-0142-9

Other articles of this Issue 1/2015

Journal of Experimental & Clinical Cancer Research 1/2015 Go to the issue

Research

HOXD9 promotes epithelial–mesenchymal transition and cancer metastasis by ZEB1 regulation in hepatocellular carcinoma

Research article

Metformin can block precancerous progression to invasive tumors of bladder through inhibiting STAT3-mediated signaling pathways

Research

Hematopoietic neoplasms in Prkar2a-deficient mice

Research

Neuron navigator 2 overexpression indicates poor prognosis of colorectal cancer and promotes invasion through the SSH1L/cofilin-1 pathway

Research

Inhibition of autophagy by 3-MA enhances IL-24-induced apoptosis in human oral squamous cell carcinoma cells

Research

Karyopherin alpha 2 is a novel prognostic marker and a potential therapeutic target for colon cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits